Diverse Biochemical Properties of Shp2 Mutants
暂无分享,去创建一个
Malcolm McGregor | Lewis C Cantley | M. McGregor | L. Cantley | B. Neel | Heike Keilhack | F. S. David | Benjamin G Neel | H. Keilhack | Frank S David
[1] M. Loh,et al. Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. , 2004, Blood.
[2] Jie Wu,et al. Noonan syndrome–associated SHP2/PTPN11 mutants cause EGF‐dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation , 2004, Human mutation.
[3] D. Barford,et al. Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. , 2000, Molecular cell.
[4] T. Pawson,et al. The 64-kDa protein that associates with the platelet-derived growth factor receptor beta subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[5] Bruce D Gelb,et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. , 2002, American journal of human genetics.
[6] J. Noonan. Noonan syndrome revisited. , 1999, The Journal of pediatrics.
[7] D. Barford,et al. Visualization of the Cysteinyl-phosphate Intermediate of a Protein-tyrosine Phosphatase by X-ray Crystallography* , 1998, The Journal of Biological Chemistry.
[8] Xinyang Zheng,et al. Cell transformation and activation of pp60c-src by overexpression of a protein tyrosine phosphatase , 1992, Nature.
[9] Z. Zhao,et al. A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[10] Michael A. Patton,et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome , 2001, Nature Genetics.
[11] J. Kuriyan,et al. Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase. , 1994, Structure.
[12] H. Ropers,et al. Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome , 2003, European Journal of Human Genetics.
[13] K. Lim,et al. Targeted disruption of the tyrosine phosphatase PTPα leads to constitutive downregulation of the kinases Src and Fyn , 1999, Current Biology.
[14] C. Walsh,et al. Potent Stimulation of SH-PTP2 Phosphatase Activity by Simultaneous Occupancy of Both SH2 Domains (*) , 1995, The Journal of Biological Chemistry.
[15] B. Neel,et al. The "Gab" in signal transduction. , 2003, Trends in cell biology.
[16] B. Neel,et al. Activated Mutants of SHP-2 Preferentially Induce Elongation of Xenopus Animal Caps , 2000, Molecular and Cellular Biology.
[17] M. Loh,et al. SHP-2 and myeloid malignancies. , 2004, Current opinion in hematology.
[18] B. Gelb,et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. , 2004, Blood.
[19] B. Neel,et al. Tyrosyl Phosphorylation of Shp2 Is Required for Normal ERK Activation in Response to Some, but Not All, Growth Factors* , 2003, Journal of Biological Chemistry.
[20] M. White,et al. IRS proteins and the common path to diabetes. , 2002, American journal of physiology. Endocrinology and metabolism.
[21] C. Walsh,et al. Activation of the SH2-containing protein tyrosine phosphatase, SH-PTP2, by phosphotyrosine-containing peptides derived from insulin receptor substrate-1. , 1994, The Journal of biological chemistry.
[22] H. Ohashi,et al. Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia , 2005, Journal of Human Genetics.
[23] S. Shoelson,et al. Crystal Structure of the Tyrosine Phosphatase SHP-2 , 1998, Cell.
[24] H. Kanegane,et al. Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. , 2004, The Journal of clinical endocrinology and metabolism.
[25] B. Marino,et al. Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal. , 1999, The Journal of pediatrics.
[26] M. Loh,et al. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group , 2004, Leukemia.
[27] K. Sharp,et al. Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.
[28] M. Loh,et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. , 2004, Blood.
[29] B. Jenkins,et al. Acquiring signalling specificity from the cytokine receptor gp130. , 2004, Trends in genetics : TIG.
[30] B. Neel,et al. Isolation of a src homology 2-containing tyrosine phosphatase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[31] D. Seripa,et al. Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes , 2003, Journal of medical genetics.
[32] C. Walsh,et al. Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor. , 1993, The Journal of biological chemistry.
[33] John D. Minna,et al. Activating Mutations of the Noonan Syndrome-Associated SHP2/PTPN11 Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia , 2004, Cancer Research.
[34] B. Neel,et al. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. , 2003, Trends in biochemical sciences.
[35] K. Kosaki,et al. Somatic PTPN11 mutation with a heterogeneous clonal origin in children with juvenile myelomonocytic leukemia , 2004, Leukemia.
[36] Michael B Yaffe,et al. BRCT Repeats As Phosphopeptide-Binding Modules Involved in Protein Targeting , 2003, Science.
[37] J. Kutok,et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. , 2005, Cancer cell.
[38] S. Harrison,et al. Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2 , 1996, Nature.
[39] J. Licht,et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.
[40] B. Kennedy,et al. Attenuation of Adhesion-dependent Signaling and Cell Spreading in Transformed Fibroblasts Lacking Protein Tyrosine Phosphatase-1B , 2001, The Journal of Biological Chemistry.
[41] R. Gibbs,et al. PTPN11 Mutations in Noonan syndrome type I: detection of recurrent mutations in exons 3 and 13 , 2002, Human mutation.
[42] R. Weening,et al. Noonan's syndrome in association with acute leukemia. , 1995, Pediatric hematology and oncology.
[43] J Godovac-Zimmermann,et al. Phosphotyrosine 1173 Mediates Binding of the Protein-tyrosine Phosphatase SHP-1 to the Epidermal Growth Factor Receptor and Attenuation of Receptor Signaling* , 1998, The Journal of Biological Chemistry.
[44] T Pawson,et al. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[45] J. Sap,et al. Receptor protein tyrosine phosphatase α activates Src-family kinases and controls integrin-mediated responses in fibroblasts , 1999, Current Biology.
[46] C. Walsh,et al. Expression, purification, and characterization of SH2-containing protein tyrosine phosphatase, SH-PTP2. , 1993, The Journal of biological chemistry.
[47] Charis Eng,et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling , 1995, Nature.